donanemab – MOSAEC

Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.

By Gina Kolata and Pam Belluck

donanemab Drugs (Pharmaceuticals) Eli Lilly and Company Food and Drug Administration

F.D.A. Delays Action on Closely Watched Alzheimer’s Drug

Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.

By Pam Belluck

donanemab Drugs (Pharmaceuticals) Leqembi (Drug) Proteins Research

Treating Alzheimer’s Very Early Offers Better Hope of Slowing Decline, Study Finds

A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.

By Pam Belluck